CTLA4Ig: Bridging the Basic Immunology with Clinical Application

Overview

Journal Immunity

Publisher Cell Press

Specialty Allergy & Immunology

Date 2006 Mar 21

PMID 16546089

Citations 106

Authors

Jeffrey A Bluestone

E William St Clair

Laurence A Turka

Affiliations

Soon will be listed here.

Abstract

After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.

Citing Articles

Follicular regulatory T cells restrain kidney allograft rejection in mice by suppressing alloreactive B cells.

Zhang H, Podesta M, Cavazzoni C, Wu Y, Lee J, Li X Nat Commun. 2025; 16(1):2151.

PMID: 40038336 PMC: 11880397. DOI: 10.1038/s41467-025-57468-4.

STAT3 phosphorylation in the rheumatoid arthritis immunological synapse.

Kotzer H, Capera J, Jainarayanan A, Mayya V, Zanin-Zhorov A, Valvo S bioRxiv. 2025; .

PMID: 39896614 PMC: 11785017. DOI: 10.1101/2025.01.20.633875.

In vivo affinity maturation of the CD4 domains of an HIV-1-entry inhibitor.

Pan A, Bailey C, Ou T, Xu J, Aristotelous T, Liu X Nat Biomed Eng. 2024; 8(12):1715-1729.

PMID: 39638875 DOI: 10.1038/s41551-024-01289-1.

Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy.

Mok S, Agac Cobanoglu D, Liu H, Mancuso J, Allison J Proc Natl Acad Sci U S A. 2024; 121(27):e2404661121.

PMID: 38923991 PMC: 11228532. DOI: 10.1073/pnas.2404661121.

High dimensional proteomic mapping of bone marrow immune characteristics in immune thrombocytopenia.

Liu F, Qu Q, Lei Y, Chen Q, Chen Y, Li M Sci China Life Sci. 2024; 67(8):1635-1647.

PMID: 38644444 DOI: 10.1007/s11427-023-2520-4.